Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.

Yao JC.

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):163-72. Review.

PMID:
17382271
2.

Molecular targeted therapy for neuroendocrine tumors.

Yao JC, Hoff PM.

Hematol Oncol Clin North Am. 2007 Jun;21(3):575-81; x. Review.

PMID:
17548041
3.

Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.

Nakakura EK, Bergsland EK.

Hematol Oncol Clin North Am. 2007 Jun;21(3):457-73; viii. Review.

PMID:
17548034
4.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
5.

Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN.

J Natl Cancer Inst. 2013 Jul 17;105(14):1005-17. doi: 10.1093/jnci/djt135. Epub 2013 Jul 9. Review.

6.

The evolving landscape of neuroendocrine tumors.

Bergsland EK.

Semin Oncol. 2013 Feb;40(1):4-22. doi: 10.1053/j.seminoncol.2012.11.013. Review. Erratum in: Semin Oncol. 2013 Apr;40(2):239.

PMID:
23391109
7.

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Reidy-Lagunes D, Thornton R.

Curr Oncol Rep. 2012 Jun;14(3):249-56. doi: 10.1007/s11912-012-0232-1. Review.

PMID:
22434313
8.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

9.

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.

Wiedenmann B, Pavel M, Kos-Kudla B.

Neuroendocrinology. 2011;94(3):177-90. doi: 10.1159/000329386. Epub 2011 Aug 31. Review.

10.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
11.

Endocrine tumors of the pancreas.

House MG, Schulick RD.

Curr Opin Oncol. 2006 Jan;18(1):23-9. Review. Retraction in: Klastersky J. Curr Opin Oncol. 2006 Jul;18(4):414.

PMID:
16357560
12.

Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).

Desai KK, Khan MS, Toumpanakis C, Caplin ME.

Minerva Gastroenterol Dietol. 2009 Dec;55(4):425-43. Review.

PMID:
19942827
13.

Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.

Miljković MD, Girotra M, Abraham RR, Erlich RB.

Dig Dis Sci. 2012 Jan;57(1):9-18. doi: 10.1007/s10620-011-1854-0. Epub 2011 Sep 22. Review.

PMID:
21938486
14.

RET and neuroendocrine tumors.

Murakumo Y, Jijiwa M, Asai N, Ichihara M, Takahashi M.

Pituitary. 2006;9(3):179-92. Review.

PMID:
17036197
15.

Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.

Faivre S, Sablin MP, Dreyer C, Raymond E.

Endocrinol Metab Clin North Am. 2010 Dec;39(4):811-26. doi: 10.1016/j.ecl.2010.09.006. Review.

PMID:
21095547
16.

New treatment options for patients with advanced neuroendocrine tumors.

Chan JA, Kulke MH.

Curr Treat Options Oncol. 2011 Jun;12(2):136-48. doi: 10.1007/s11864-011-0148-2. Review.

PMID:
21437592
17.

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.

Capurso G, Archibugi L, Delle Fave G.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):594-601. doi: 10.1002/jhbp.210. Epub 2015 Jan 25. Review.

PMID:
25619712
18.

Islet cell tumors.

Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ.

Curr Probl Surg. 2006 Oct;43(10):685-765. Review. No abstract available.

PMID:
17055796
19.
20.

Current treatment options for neuroendocrine tumors.

Hörsch D, Grabowski P, Schneider CP, Petrovitch A, Kaemmerer D, Hommann M, Baum RP.

Drugs Today (Barc). 2011 Oct;47(10):773-86. doi: 10.1358/dot.2011.47.10.1673555. Review. Erratum in: Drugs Today (Barc). 2012 Feb;48(2):172.

PMID:
22076492
Items per page

Supplemental Content

Write to the Help Desk